Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Pilot Projects Initiated to Create Cancer Genomics Cloud

By BiotechDaily International staff writers
Posted on 03 Feb 2014
The US National Cancer Institute (NCI; Rockville, MD, USA) has allotted USD 20 million for cloud-based genomics pilot projects, realizing that it is faced with rising data struggles. Because the scale of its projects increases—one initiative is expected to generate 2.5 petabytes of data—downloading analysis findings on local systems becomes unrealistic.

The NCI is now seeking organizations that can help in its goals, having spent 2013 collecting on user feedback oh what they need from cloud-based cancer genomics. The plan is to promote the development of multiple pilot projects that will undergo a competitive assessment. The NCI, after consulting with cancer researchers, will select one or more of the projects, or a modification of them, as the production version. Finally, the project will be sourced into a Cancer Knowledge Commons that aggregates all data.

The last phase of the project is to optimize NCI-generated data access by decreasing the technical requirements for researchers. Data are downloaded, in the current system, for analysis with locally developed and run tools. The dependence on local systems translates into organizations without top-tier computing power and capabilities can do less with the data. Correspondingly, storing petabytes of data is impractical for some groups. With data pools growing quickly, storage costs will also increase.

The NCI views cloud-based genomics systems will serve as the solution. Storing data and running analysis tools in the cloud will lessen the computing power needed for end users to search for clues in the results. Even prominent research institutions should benefit from using a cloud-based system, as data download times are on the cusp of becoming impractical. Using a point-to-point 10-gigabit network, downloading the 2.5 petabytes generated by the Cancer Genome Atlas would take weeks.

The NCI’s new initiative will be, as aforementioned, the first step toward the establishment of a full Cancer Knowledge Commons, relative to the US National Academy report on Precision Medicine, and will be coordinated with the National Institutes of Health’s (Bethesda, MD, USA) Big Data to Knowledge (BD2K) initiative and other pertinent activities in large-scale data analysis.

Related Links:

US National Cancer Institute



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.